Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

June 17, 2021 By The ASCO Post Staff

Efstathios Kastritis, MD, of the University of Athens, discusses updated phase III results from the ANDROMEDA study of patients with newly diagnosed light chain amyloidosis. The trial further supports the use of daratumumab plus VCd (bortezomib, cyclophosphamide, and dexamethasone), which was shown to be clinically superior to VCd alone (Abstract S189).

Related Content